ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study.


Journal

Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519

Informations de publication

Date de publication:
04 2019
Historique:
received: 28 08 2018
accepted: 03 02 2019
pubmed: 24 2 2019
medline: 21 1 2020
entrez: 24 2 2019
Statut: ppublish

Résumé

Platinum-based doublets are the standard chemotherapy for lung cancer. The identification of markers associated with drug toxicity may improve the success of the treatment. Single nucleotide polymorphisms (SNPs) mapping into the genes involved in platinum transport or detoxification may explain the occurrence of toxicities. In this study, we evaluated the role of three SNPs in predicting the onset of adverse events for lung cancer patients receiving cisplatin or carboplatin in adjuvant, neo-adjuvant and metastatic settings. Eighty-two patients affected by non-small-cell and small-cell lung cancer treated with cisplatin- or carboplatin-based chemotherapy (stage II-IV) were enrolled. Before genetic analysis, patients signed a written informed consent. DNA was extracted from peripheral blood samples and genotypes were determined by real-time PCR. We selected and analyzed three SNPs: ABCB1 c.3435C>T/rs1045642, ABCC2 -24C>T/rs717620 and GSTP1 c.313A>G/rs1695. Patient characteristics and genotypes were correlated with hematological, gastrointestinal and renal toxicity as recorded by Common Terminology Criteria for Adverse Event (CTCAE) v4.03. No neurological toxicity was observed in our patients. Variant alleles were present in 53% of patients for ABCB1 c.3435C >T, 18.3% for ABCC2 -24C> T, and 34.8% for GSTP1 c.313A>G. Heterozygous CT at ABCB1 c.3435 was associated to a lower risk of hematological toxicity compared to homozygous CC (OR = 0.20; 95% CI 0.05, 0.69; p = 0.01). Similar results were observed by genetic dominant model (CT + TT vs CC) and hematological toxicity (OR = 0.26; 95% CI 0.09, 0.79; p = 0.02). No other significant associations were found between toxicity and SNPs. Multivariate analysis confirmed an independent value for the ABCB1 c.3435 C >T polymorphism. The present study reveals that ABCB1 c.3435C>T polymorphism influences platinum toxicity. The T allele seems to exert a protective effect on the development of toxicities. Further studies, such as epigenetic regulation ones, are needed to validate and shed more light on this association.

Sections du résumé

BACKGROUND
Platinum-based doublets are the standard chemotherapy for lung cancer. The identification of markers associated with drug toxicity may improve the success of the treatment. Single nucleotide polymorphisms (SNPs) mapping into the genes involved in platinum transport or detoxification may explain the occurrence of toxicities. In this study, we evaluated the role of three SNPs in predicting the onset of adverse events for lung cancer patients receiving cisplatin or carboplatin in adjuvant, neo-adjuvant and metastatic settings.
METHODS
Eighty-two patients affected by non-small-cell and small-cell lung cancer treated with cisplatin- or carboplatin-based chemotherapy (stage II-IV) were enrolled. Before genetic analysis, patients signed a written informed consent. DNA was extracted from peripheral blood samples and genotypes were determined by real-time PCR. We selected and analyzed three SNPs: ABCB1 c.3435C>T/rs1045642, ABCC2 -24C>T/rs717620 and GSTP1 c.313A>G/rs1695. Patient characteristics and genotypes were correlated with hematological, gastrointestinal and renal toxicity as recorded by Common Terminology Criteria for Adverse Event (CTCAE) v4.03. No neurological toxicity was observed in our patients.
RESULTS
Variant alleles were present in 53% of patients for ABCB1 c.3435C >T, 18.3% for ABCC2 -24C> T, and 34.8% for GSTP1 c.313A>G. Heterozygous CT at ABCB1 c.3435 was associated to a lower risk of hematological toxicity compared to homozygous CC (OR = 0.20; 95% CI 0.05, 0.69; p = 0.01). Similar results were observed by genetic dominant model (CT + TT vs CC) and hematological toxicity (OR = 0.26; 95% CI 0.09, 0.79; p = 0.02). No other significant associations were found between toxicity and SNPs. Multivariate analysis confirmed an independent value for the ABCB1 c.3435 C >T polymorphism.
CONCLUSIONS
The present study reveals that ABCB1 c.3435C>T polymorphism influences platinum toxicity. The T allele seems to exert a protective effect on the development of toxicities. Further studies, such as epigenetic regulation ones, are needed to validate and shed more light on this association.

Identifiants

pubmed: 30796464
doi: 10.1007/s00280-019-03794-6
pii: 10.1007/s00280-019-03794-6
doi:

Substances chimiques

ABCB1 protein, human 0
ABCC2 protein, human 0
ATP Binding Cassette Transporter, Subfamily B 0
Multidrug Resistance-Associated Protein 2 0
Carboplatin BG3F62OND5
Cisplatin Q20Q21Q62J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

803-808

Auteurs

Beatrice De Troia (B)

Department of Oncology, ASST Fatebenefratelli-Sacco, Via Giovanni Battista Grassi, 74 20157, Milan, Italy. beadt83@gmail.com.

Davide Dalu (D)

Department of Oncology, ASST Fatebenefratelli-Sacco, Via Giovanni Battista Grassi, 74 20157, Milan, Italy.

Virginio Filipazzi (V)

Department of Oncology, ASST Fatebenefratelli-Sacco, Via Giovanni Battista Grassi, 74 20157, Milan, Italy.

Luigi Isabella (L)

Department of Oncology, ASST Fatebenefratelli-Sacco, Via Giovanni Battista Grassi, 74 20157, Milan, Italy.

Nicoletta Tosca (N)

Department of Oncology, ASST Fatebenefratelli-Sacco, Via Giovanni Battista Grassi, 74 20157, Milan, Italy.

Sabrina Ferrario (S)

Department of Oncology, ASST Fatebenefratelli-Sacco, Via Giovanni Battista Grassi, 74 20157, Milan, Italy.

Anna Rita Gambaro (AR)

Department of Oncology, ASST Fatebenefratelli-Sacco, Via Giovanni Battista Grassi, 74 20157, Milan, Italy.

Luisa Somma (L)

Department of Oncology, ASST Fatebenefratelli-Sacco, Via Giovanni Battista Grassi, 74 20157, Milan, Italy.

Cinzia Fasola (C)

Department of Oncology, ASST Fatebenefratelli-Sacco, Via Giovanni Battista Grassi, 74 20157, Milan, Italy.

Stefania Cheli (S)

Unit of Clinical Pharmacology, Department of Laboratory Medicine, ASST Fatebenefratelli-Sacco, Milan, Italy.

Emilio Clementi (E)

Scientific Institute, IRCCS E. Medea, Bosisio Parini, Lecco, Italy.
Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, Consiglio Nazionale delle Ricerche Institute of Neuroscience, University Hospital "Luigi Sacco", Università di Milano, Milan, Italy.

Davide De Francesco (D)

Department of Infection and Population Health, UCL, London, UK.

Felicia Stefania Falvella (FS)

Unit of Clinical Pharmacology, Department of Laboratory Medicine, ASST Fatebenefratelli-Sacco, Milan, Italy.

Maria Teresa Cattaneo (MT)

Department of Oncology, ASST Fatebenefratelli-Sacco, Via Giovanni Battista Grassi, 74 20157, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH